HR-Positive, HER2-Negative Metastatic Breast Cancer
- 14 pages
- Spiral Bound
- 80# Aqueous Coating
- 4.25" x 7.25"
- Ships in 5 – 10 business days
A digital version of this pocket guide is available for FREE at this link
- Introduction
- Treatment
- Recommendations from 2024 Rapid Recommendation Update
- Recommendations from 2023 Rapid Recommendation Update
- Recommendations from 2021 Focused Guideline Update
- Recommendations Unchanged from 2016 Guideline
- Tables
- Treatment Options According to Prior Endocrine Therapy
- At-A-Glance Guide to ASCO Biomarker Testing in Metastatic Breast Cancer Recommendations
- Algorithm
- Algorithm for Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
- For purchases under 100 in quantity, we suggest placing the order directly through the website.
- We offer group/institutional licenses for multi-user accounts (discount amount varies depending on the number of users).
- We are proud to offer special discounts to medical schools, training programs, students and more.
- We offer bulk purchase discounts based on number of copies and number of titles.
Contact Us for more details
Description
This pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
You can also find this product included in this bundle!
- Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
- Adjuvant Therapy for Stage III Colon Cancer
- Advanced Gastroesophageal Cancer
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer – Brain Metastases
- Antiemetics
- Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
- Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology
- Anxiety and Depression in Adult Survivors of Cancer
- Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
- Axilla Management in Early-Stage Breast Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Bone-Modifying Agents in Metastatic Breast Cancer
- Bone-Modifying Agents in Multiple Myeloma
- Breast Cancer Germline Testing
- Cancer Survivorship for People Affected by Advanced or Metastatic Cancer
- Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
- Cannabis in Adults with Cancer
- Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
- Cervical Cancer Prevention
- Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
- Chemotherapy-Naïve Castration-Resistant Prostate Cancer
- Chronic Pain in Survivors of Adult Cancers
- Clear Cell Renal Cell Carcinoma
- Colorectal Cancer Biomarkers
- Colorectal Cancer Early Detection
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
- Diffuse Astrocytic and Oligodendroglial Tumors in Adults
- Early-Stage Breast Cancer
- Estrogen and Progesterone Receptor Testing in Breast Cancer
- Exercise, Diet, and Weight Management During Cancer Treatment
- Fatigue in Adult Survivors of Cancer
- Fertility Preservation
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
- Germline Genetic Testing for Cancer
- Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
- HER2 Testing in Breast Cancer
- Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
- HR-Positive, HER2-Negative Metastatic Breast Cancer
- Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy
- Immune-related Adverse Events — CAR T-Cell Therapy
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
- Integrative Medicine for Pain Management in Oncology
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adult Patients with Cancer
- Invasive Cervical Cancer
- Laryngeal Cancer
- Late-Stage Colorectal Cancer
- Locally Advanced Rectal Cancer
- Lung Cancer Surveillance After Definitive Curative-Intent Therapy
- Malignant Pleural Mesothelioma
- Management of Cancer Cachexia
- Management of Dyspnea in Advanced Cancer
- Management of Hereditary Breast Cancer
- Management of Male Breast Cancer
- Management of Osteoporosis
- Management of Salivary Gland Malignancy
- Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Medication-Related Osteonecrosis of the Jaw
- Metastatic Colorectal Cancer
- Metastatic HER2-Negative Breast Cancer – Chemo- and Targeted Therapy
- Metastatic Pancreatic Cancer
- Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Molecular Biomarkers in Localized Prostate Cancer
- Multiple Myeloma
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA
- Optimum Imaging Strategies for Advanced Prostate Cancer
- Osteoradionecrosis in Patients With Head and Neck Cancer
- Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- Ovarian Masses and Treatment of Epithelial Ovarian Cancer
- Palliative Care
- Palliative Care in the Global Setting
- Pancreatic Cancer - Evaluating Susceptibility
- PARP Inhibitors in the Management of Ovarian Cancer
- Penile Cancer
- Platelet Transfusion
- Potentially Curable Pancreatic Adenocarcinoma
- Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
- Recurrent and Metastatic Head and Neck Cancers
- Salivary Gland Hypofunction and/or Xerostomia
- Secondary Prevention of Cervical Cancer
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
- Small Renal Masses
- Somatic Genomic Testing for Metastatic or Advanced Cancer
- Stage II Colon Cancer Adjuvant Therapy
- Stage III Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Systemic Therapy for Advanced Hepatocellular Carcinoma
- Systemic Therapy for Melanoma
- Systemic Therapy for Small Cell Lung Cancer
- Systemic Treatment of Patients With Metastatic Breast Cancer
- Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
- Treatment for Brain Metastases
- Treatment of Early-Stage Colorectal Cancer
- Treatment of Locally Advanced Esophageal Carcinoma
- Treatment of Metastatic Carcinoma and Myeloma of the Femur
- Use of Endocrine Therapy for Breast Cancer Risk Reduction
- Use of Opioids for Cancer Pain
- Vaccination of Adults with Cancer
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
- Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
- White Blood Cell Growth Factors